Irbesartan/Hydrocholorthiazide Teva

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Teva, is an Angiotensin II receptor blocker presented as a fixed‑dose oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients. The combination leverages the vasodilatory effect of irbesartan together with the diuretic action of hydrochlorothiazide, offering a synergistic approach to blood‑pressure control and reducing the need for multiple separate pills.

GNH USA supplies Irbesartan/Hydrochlorothiazide Teva as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and providing reliable bulk shipments to hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that targets the renin‑angiotensin system and promotes diuresis.

Hypertension (essential): lowers systolic and diastolic blood pressure, helping achieve target levels. High blood pressure with fluid retention: provides combined vasodilation and diuretic effect to improve overall control. Resistant hypertension (as adjunct): adds a diuretic component to enhance efficacy when monotherapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or mild weakness. - Increased urinary frequency. - Mild electrolyte changes such as low potassium. - Transient nausea.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia). - Acute kidney injury or worsening renal function. - Angioedema or severe allergic reactions. - Marked hypotension. - Pancreatitis (rare). - Severe gout attacks.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess efficacy. - Assess renal function and serum electrolytes, especially potassium and creatinine. - Use caution in patients with hepatic impairment. - Avoid in individuals with severe volume depletion or salt‑losing conditions. - Adjust dose in the elderly or in patients with reduced renal function. - Store at room temperature: keep in the original pack, protect from moisture.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Review the following groups:

Major Interactions (Avoid): - Aliskiren in diabetic patients (risk of renal impairment and hyperkalemia). - Potassium‑sparing diuretics or supplements (risk of hyperkalemia). - ACE inhibitors or other ARBs (excessive renal dysfunction, hyperkalemia). - NSAIDs (may blunt antihypertensive effect and affect renal function). - Lithium (increased lithium toxicity).

Moderate Interactions (Monitor Closely): - Other antihypertensives (additive blood‑pressure lowering). - Loop or thiazide diuretics (enhanced electrolyte loss). - Antidiabetic agents (possible need for dose adjustment). - Anticoagulants (potential increase in INR). - Strong CYP3A4 inhibitors (may raise irbesartan plasma levels).